Thermo Fisher Scientific Reports First Quarter 2025 Results

Original from: Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 29, 2025.

First Quarter Highlights

· First quarter revenue was $10.36 billion.

· First quarter GAAP diluted earnings per share (EPS) grew 15% to $3.98.

· First quarter adjusted EPS grew 1% to $5.15.

· Delivered very strong financial performance in the quarter, demonstrating the strength of our trusted partner status and the power of our PPI Business System in a more uncertain macroeconomic environment.

· Advanced our proven growth strategy, launching a range of high-impact, innovative new products during the quarter. To transform semiconductor analysis, we introduced the Thermo Scientific™ Vulcan™ Automated Lab, a groundbreaking system integrating robotic sample handling, artificial intelligence, and electron microscopy, helping semiconductor manufacturers enhance productivity, increase yields, reduce costs and ensure high quality. To advance precision medicine, we introduced Olink® Reveal proteomics kits that enable the identification of proteins related to inflammation and immune response. And we launched Thermo Scientific™ Cryofuge™, Thermo Scientific™ BIOS and Thermo Scientific™ LYNX, a suite of floor model centrifuges incorporating next-generation natural refrigerant technology and designed to deliver high performance with meaningful energy savings.

· Strengthened our industry-leading commercial engine and deepened our trusted partner status with customers to accelerate innovation and enhance productivity. Examples during the quarter included a Technology Alliance Agreement with the Chan Zuckerberg Institute for Advanced Biological Imaging focused on developing new technologies to enable researchers to better visualize human cells, significantly advancing scientific research and discovery. To gain insights about the safety and effectiveness of current and future treatments, Thermo Fisher launched CorEvitas clinical registries in Systemic Lupus Erythematosus and Adolescent Alopecia Areata to collect clinical data, monitor disease progression, treatment effectiveness, and healthcare outcomes.

· Continued to successfully execute our capital deployment strategy. During the quarter, we entered into an agreement to acquire Solventum’s Purification & Filtration Business for $4.1 billion in cash, repurchased $2.0 billion of stock and increased our dividend by 10%.

“We delivered very strong performance in the first quarter in a more uncertain macroeconomic environment, and I’m incredibly proud of our team's execution,” said Marc N. Casper, chairman, president, and chief executive officer of Thermo Fisher Scientific. “Our team leveraged the PPI Business System to drive operational excellence and enable our customers’ success.”

Casper added: “Thermo Fisher is incredibly well-positioned. Our experienced management team has a proven track record, and as the trusted partner to our customers, we will help them manage the current environment, identifying new opportunities and ultimately creating value for all our stakeholders.”

First Quarter 2025

Revenue for the quarter was $10.36 billion in 2025 versus $10.34 billion in the same quarter of 2024. Organic revenue growth was 1%.

GAAP Earnings Results

GAAP diluted EPS in the first quarter of 2025 was $3.98, versus $3.46 in the same quarter last year. GAAP operating income for the first quarter of 2025 was $1.72 billion, compared with $1.66 billion in the year-ago quarter. GAAP operating margin was 16.6%, compared with 16.1% in the first quarter of 2024.

Non-GAAP Earnings Results

Adjusted EPS in the first quarter of 2025 was $5.15, versus $5.11 in the first quarter of 2024. Adjusted operating income for the first quarter of 2025 was $2.27 billion, compared with $2.28 billion in the year-ago quarter. Adjusted operating margin was 21.9%, compared with 22.0% in the first quarter of 2024.

Annual Guidance for 2025

The company will provide updated 2025 financial guidance during its earnings conference call this morning at 8:30 a.m. Eastern Time.

Source: Thermo Fisher Scientific Reports First Quarter 2025 Results